


Stabilis



Buprenorphine hydrochloride



Noms commerciaux

Bunondol	Pologne
Buprenex	Etats Unis d'Amérique
Buprex	Espagne
Sublocade	
Temgesic	Belgique, Danemark, Emirats Arabes Unis, France, Grande Bretagne, Italie, Norvège, Pays bas, Suède, Tunisie







Stabilité des solutions

		0,03 mg/ml	1-9°C		180			4314
		0,03 mg/ml	18-24°C		180			4314







Stabilité en mélange

PVC		57 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30		2113
PVC		57 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	9		2113
PVC		57 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30		2113
PP		57 mg/ml	21°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30		2113
PP		57 mg/ml	36°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	16		2113

		57 mg/ml	4°C		Glycopyrronium bromide : 15 mg/ml Haloperidol lactate : 52 mg/ml	30		2113
--	--	----------	-----	--	---	----	--	------












Facteur influençant la stabilité

				4314
---	---	---	---	------



Compatibilités

			
	Buprenorphine hydrochloride : 0.04 mg/ml Allopurinol sodium : 3 mg/ml		307
			921
	Buprenorphine hydrochloride : 0.04 mg/ml Cladribine : 0.5 mg/ml		1496
	Buprenorphine hydrochloride : 0.04 mg/ml Cladribine : 0.015 mg/ml		1496
	Buprenorphine hydrochloride : 0.04 mg/ml		301
	Buprenorphine hydrochloride : 0.04 mg/ml		1415
	Buprenorphine hydrochloride : 0.04 mg/ml Amifostine : 10 mg/ml		3
	Buprenorphine hydrochloride : 0.04 mg/ml Aztreonam : 40 mg/ml		99
	Buprenorphine hydrochloride : 0.04 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Buprenorphine hydrochloride : 0.04 mg/ml Docetaxel : 0.9 mg/ml		1754
			251
	Buprenorphine hydrochloride : 0.04 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Buprenorphine hydrochloride : 0.04 mg/ml Filgrastim : 30 µg/ml		244
			1232
	Buprenorphine hydrochloride : 0.04 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Buprenorphine hydrochloride : 0.04 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
			1625
	Buprenorphine hydrochloride : 0.04 mg/ml Linezolid : 2 mg/ml		1925
	Buprenorphine hydrochloride : 0.04 mg/ml Melphalan : 0.1 mg/ml		169

	Buprenorphine hydrochloride : 0.15 mg/ml Midazolam hydrochloride : 2.5 mg/ml	∅	404
	Buprenorphine hydrochloride : 0,04 mg/ml Oxaliplatin : 0,5 mg/ml	◆	1662
	Buprenorphine hydrochloride : 0.04 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
	Buprenorphine hydrochloride : 0.04 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
	Buprenorphine hydrochloride : 0.04 mg/ml Propofol : 10 mg/ml	∅	300
	Buprenorphine hydrochloride : 0.04 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
	Buprenorphine hydrochloride : 0.04 mg/ml Teniposide : 0.1 mg/ml	◆	905
	Buprenorphine hydrochloride : 0.04 mg/ml Thiotepa : 1 mg/ml	◆	249
	Buprenorphine hydrochloride : 0.04 mg/ml Vinorelbine tartrate : 1 mg/ml	▲	84



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.

244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
404	Revue	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.

1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2113	Revue	Jäppinen A, Kokki H, Naaranlahti TJ, Rasi AS. Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 1999 ; 21, 6: 272-274.
4314	Revue	DenHerder J.M, Reed R.L, Sargent J.L, Bobe G, Stevens J.F, Helen E Diggs H.E. Effects of Time and Storage Conditions on the Chemical and Microbiologic Stability of Diluted Buprenorphine for Injection. J Am Pharm Assoc 2017 ; 56, 4: 457-461.



Dictionnaire

 Antalgique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 NaCl 0,9% + bactériostatique	 A l'abri de la lumière
 Jour	 Stabilité en mélange
 Solvant	 Molécule
 Polyvinyl chlorure	 Chlorure de sodium 0,9%
 Polypropylène	 Facteur influençant la stabilité
 Seringue polypropylène	 Provoque
 Diminution de la stabilité	 Compatibilités
 Compatible	 Précipitation immédiate
 Incompatible	 Glucose 5%
 Nutrition parentérale (mélange binaire)	 Nutrition parentérale (mélange ternaire)
 Perte de turbidité	 Turbidité en 4 heures
 Eau pour préparation injectable	 Aucun
 Voie d'administration	 Intraveineuse
 Intramusculaire	 Sous cutanée
 Perfusion SC continue	 Bibliographie
 Dictionnaire	